Back

argenx SE

Below you will find information from the register publication of inside information. The information has been provided by the organisation.

  • Registration date 14 jun 2018 - 07:00
  • Statutory name argenx SE
  • Title argenx announces data from Phase 1 study of efgartigimod (ARGX-113) subcutaneous formulation demonstrating comparable characteristics to intravenous formulation

Related downloads

201806140000000001_argenx announces data from Phase 1 study of efgartigimod (ARGX-113) subcutaneous formulation demonstrating comparable characteristics to intravenous formulation.docx

Date last update: 19 November 2018

Share information

Share on: Share this